Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35520: Variant p.Glu144Lys

Cystathionine beta-synthase
Gene: CBS
Feedback?
Variant information Variant position: help 144 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glutamate (E) to Lysine (K) at position 144 (E144K, p.Glu144Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CBSD; loss of cystathionine beta-synthase activity; impaired stimulation by AdoMet and AdoHcy; decreased homotetramer formation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 144 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 551 The length of the canonical sequence.
Location on the sequence: help LRMIEDAERDGTLKPGDTII E PTSGNTGIGLALAAAVRGYR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LRMIEDAERDGTLKPG-DTIIEPTSGNTGIGLALAAAVRGYR

Mouse                         LRMIEDAERAGNLKPG-DTIIEPTSGNTGIGLALAAAVKGY

Rat                           LRMIEDAERAGTLKPG-DTIIEPTSGNTGIGLALAAAVKGY

Rabbit                        LRMIEDAERAGTLRPG-DTIIEPTSGNTGIGLALAAAVKGY

Slime mold                    HRMIVDAEESGRIKKG-DTLIEPTSGNTGIGLALTAAIKGY

Baker's yeast                 KSMVEEAEASGRIHPSRSTLIEPTSGNTGIGLALIGAIKGY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 551 Cystathionine beta-synthase
Binding site 149 – 149
Beta strand 141 – 145



Literature citations
Cystathionine beta-synthase mutations: effect of mutation topology on folding and activity.
Kozich V.; Sokolova J.; Klatovska V.; Krijt J.; Janosik M.; Jelinek K.; Kraus J.P.;
Hum. Mutat. 31:809-819(2010)
Cited for: CHARACTERIZATION OF VARIANTS CBSD LEU-49; ARG-65; ARG-78; ASN-102; VAL-114; GLN-125; LYS-144; ARG-148; TYR-165; LYS-176; ALA-180; MET-191; LYS-228; ARG-262; LYS-266; THR-278; LYS-302; ARG-305; SER-307; CYS-369; LEU-422; THR-435; GLN-439; ASN-444; LEU-466 AND SER-539; FUNCTION; CATALYTIC ACTIVITY; PATHWAY; ACTIVITY REGULATION; SUBUNIT; A missense mutation (I278T) in the cystathionine beta-synthase gene prevalent in pyridoxine-responsive homocystinuria and associated with mild clinical phenotype.
Shih V.E.; Fringer J.M.; Mandell R.; Kraus J.P.; Berry G.T.; Heidenreich R.A.; Korson M.S.; Levy H.L.; Ramesh V.;
Am. J. Hum. Genet. 57:34-39(1995)
Cited for: VARIANTS CBSD ARG-139; LYS-144 AND THR-278; Characterisation of five missense mutations in the cystathionine beta-synthase gene from three patients with B6-nonresponsive homocystinuria.
Dawson P.A.; Cox A.J.; Emmerson B.T.; Dudman N.P.B.; Kraus J.P.; Gordon R.B.;
Eur. J. Hum. Genet. 5:15-21(1997)
Cited for: VARIANTS CBSD LYS-144; THR-278; GLU-331; MET-353 AND GLN-439; Mutational analysis of the cystathionine beta-synthase gene: a splicing mutation, two missense mutations and an insertion in patients with homocystinuria.
Gordon R.B.; Cox A.J.; Dawson P.A.; Emmerson B.T.; Kraus J.P.; Dudman N.P.;
Hum. Mutat. 11:332-332(1998)
Cited for: VARIANTS CBSD LYS-144 AND TYR-165; Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria.
Janosik M.; Oliveriusova J.; Janosikova B.; Sokolova J.; Kraus E.; Kraus J.P.; Kozich V.;
Am. J. Hum. Genet. 68:1506-1513(2001)
Cited for: VARIANTS CBSD ARG-65; VAL-114; LYS-144; THR-155; TYR-165; LYS-176 AND THR-278; CHARACTERIZATION OF VARIANTS CBSD VAL-114; LYS-144; THR-155; TYR-165; LYS-176 AND THR-278; The molecular basis of cystathionine beta-synthase deficiency in Australian patients: genotype-phenotype correlations and response to treatment.
Gaustadnes M.; Wilcken B.; Oliveriusova J.; McGill J.; Fletcher J.; Kraus J.P.; Wilcken D.E.;
Hum. Mutat. 20:117-126(2002)
Cited for: VARIANTS CBSD LEU-49; PRO-101; ARG-109; GLN-125; LYS-144; TYR-165; LYS-228; THR-278; LYS-302; SER-307; GLU-331; CYS-336; SER-347; MET-353; CYS-369; MET-371 AND GLN-439; CHARACTERIZATION OF VARIANTS CBSD PRO-101; ARG-109; LYS-228 AND SER-347;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.